Web14 Oct 2024 · TERN-501 is a highly potent and selective small molecule THR- β agonist. About NASH Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. Web4 Nov 2024 · TERN-501-treated participants also experienced increases in sex-hormone binding globulin (SHBG), a key pharmacodynamic marker of THR-β engagement linked to decreases in levels of atherogenic...

Our Programs — Terns Pharmaceuticals

WebPhase 1 data show single doses of TERN-501 are generally well-tolerated, produce significant LDL decreases and increases in SHBG, a key ... M.D., MHSc, director of the UC San Diego NAFLD Research Center and director of Hepatology at UC San Diego School of Medicine. This presentation will highlight the safety and efficacy of TERN-101 after 12 ... WebThis phase I clinical study will evaluate the safety, tolerability and pharmacokinetics of TERN-5501 as well as pharmacodynamic biomarkers such as sex hormone Phase 1 … career manor

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH ...

Web11 Dec 2024 · Terns reported positive top-line results from the Phase 2a LIFT Study of TERN-101 in June 2024. About TERN-501 TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Web13 Jun 2024 · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics … Web地球自转一圈是一天，公转一圈是一年。但一年又一年过去，至今仍未有一款治疗非酒精性脂肪性肝炎(nash)的药物获批上市。期间，就连吉利德科学、诺华、辉瑞等全球制药巨头 career mapping in it